SCHEMBL2380915

SCHEMBL2380915

COCCCOc1cc(C)c(-c2csc(N)n2)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
GFER P55789 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 6/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
MAPT P10636 5/20 0.40
ALDH1A1 P00352 5/20 0.40
POLB P06746 3/20 0.40
LTA4H P09960 2/20 0.38
KCNH2 Q12809 1/20 0.37
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.36
RECQL P46063 1/20 0.36
LMNA P02545 1/20 0.36
NFKB1 P19838 1/20 0.36
MAPK1 P28482 1/20 0.36
NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2381713 0.93 MEN1 (0.42) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL14992624 0.91 SMN1; SMN2 (0.45) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL27916462 0.86 MAPT (0.45) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL14992797 0.84 SMN1; SMN2 (0.46) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL2381338 0.82 MEN1 (0.49) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL2381528 0.81 ALDH1A1 (0.56) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL15133469 0.80 SMN1; SMN2 (0.47) MEN1KMT2AGFERSMN1; SMN2GAA
SCHEMBL2380192 0.79 HSD17B10 (0.42) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL27916452 0.78 ALDH1A1 (0.43) MEN1KMT2AGFERHSD17B10SMN1; SMN2
SCHEMBL15133457 0.77 RAB9A (0.49) MEN1KMT2AGFERHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11071736-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION 2021-07-27 US disclosed
US-10588909-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2020-03-17 US disclosed
EP-2785714-B1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORP (TW) 2018-11-21 EP disclosed
US-20180318310-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) 2018-11-08 US disclosed
US-9409902-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2016-08-09 US disclosed
US-9409902-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2016-08-09 US disclosed
US-9409902-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2016-08-09 US disclosed
US-20150250794-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORP (TW) 2015-09-10 US disclosed
EP-2547676-B1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS INC (TW) 2015-07-29 EP disclosed
EP-2547676-B1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS INC (TW) 2015-07-29 EP disclosed
US-8946268-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS, INC. (TW) 2015-02-03 US disclosed
EP-2785714-A1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR Taivex Therapeutics Corporation (TW) 2014-10-08 EP disclosed
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-07-25 US disclosed
WO-2013082324-A1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-06-06 WO disclosed
EP-2547676-A2 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR Taivex Therapeutics Inc. (TW) 2013-01-23 EP disclosed
US-20110230486-A1 Modulators Of HEC1 Activity And Methods Therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2011-09-22 US disclosed
US-20110230486-A1 Modulators Of HEC1 Activity And Methods Therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2011-09-22 US disclosed
US-20110230486-A1 Modulators Of HEC1 Activity And Methods Therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2011-09-22 US disclosed
WO-2011115998-A2 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS INC. (CN) 2011-09-22 WO disclosed
WO-2011115998-A2 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS INC. (CN) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180318310-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 MEN1 2018/4885KMT2A 1862/4885GFER 4265/4885
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 MEN1 2018/4885KMT2A 1862/4885GFER 4265/4885
US-20150250794-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 MEN1 2018/4885KMT2A 1862/4885GFER 4265/4885
US-10588909-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 MEN1 2018/4885KMT2A 1862/4885GFER 4265/4885
US-11071736-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 MEN1 2018/4885KMT2A 1862/4885GFER 4265/4885
US-20110230486-A1 Modulators Of HEC1 Activity And Methods Therefor WEE1, WEE2, NEK11 MEN1 2061/4885KMT2A 1659/4885GFER 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.